Business Context and Reporting Period
Company: Regeneron Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Regeneron is a fully integrated biotechnology company inventing, developing, and commercializing medicines for serious diseases. Key products include EYLEA HD, EYLEA, Libtayo, Praluent, and Evkeeza. The company maintains strategic collaborations with Sanofi (Dupixent, Kevzara) and Bayer (EYLEA outside the U.S.).
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $3,605.4 million | $3,028.7 million |
| Net Product Sales | $1,534.5 million | $1,415.6 million |
| Collaboration Revenue | $1,899.7 million | $1,531.2 million |
| Net Income | $727.2 million | $808.7 million |
| Diluted EPS | $6.75 | $7.27 |
| Operating Cash Flow | $1,078.9 million | $1,045.1 million |
| Cash & Cash Equivalents | $2,962.6 million | $3,118.1 million |
| Long-Term Debt | $1,986.2 million | $1,985.9 million |
| Effective Tax Rate | 12.5% | 10.6% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 19% year-over-year, driven primarily by a 36% increase in Sanofi collaboration revenue (due to higher Dupixent sales) and a 54% increase in Libtayo global sales.
- Net Income Decline: Net income decreased 10% to $727.2 million, despite revenue growth. This was primarily due to a significant decrease in "Other income (expense), net" (down $124.7 million) caused by lower unrealized gains on marketable securities ($25.0 million vs. $139.9 million in Q1 2025).
- Product Sales Mix: EYLEA HD U.S. sales grew 53% to $468.4 million, while EYLEA U.S. sales declined 36% to $473.1 million due to competitive pressures and patient transition to EYLEA HD.
- Expense Increases: Research and Development (R&D) expenses rose 16% to $1,543.5 million, and Acquired In-Process R&D (IPR&D) expenses surged to $101.9 million from $12.3 million, related to collaboration premiums and milestone payments.
- Gross Margin Compression: Gross margin on net product sales decreased from 81% to 76%, attributed to unabsorbed manufacturing costs and inventory write-offs following a temporary production interruption at the Limerick, Ireland facility.
Guidance, Outlook, and Risks
- U.S. Government Agreements: In April 2026, Regeneron entered into agreements with the U.S. government to provide certain products to Medicaid at "Most-Favored-Nation Pricing" and to price future medicines similarly. In exchange, the company secured an exemption from Section 232 tariffs through January 2029.
- Capital Allocation: The Board authorized an additional $3.0 billion share repurchase program in April 2026. A quarterly dividend of $0.94 per share was declared in April 2026, payable in June 2026.
- Manufacturing Outlook: Production at the Limerick facility resumed in Q2 2026; however, gross margins are expected to remain negatively impacted until production returns to normal levels by the end of Q2 2026.
- Regulatory & Litigation Risks:
- EYLEA Biosimilars: Continued competition from biosimilars in the U.S. and globally is expected to negatively impact EYLEA sales. Settlements with Samsung Bioepis and Formycon delay biosimilar launches in certain regions until 2027 or May 2026, respectively.
- Sanofi Litigation: Regeneron is suing Sanofi regarding access to commercialization data for Dupixent; the court denied Sanofi's motion to dismiss in March 2026.
- Government Investigations: Ongoing civil proceedings with the U.S. Department of Justice regarding patient assistance programs and pricing reporting.
- Capital Expenditures: Full-year 2026 capital expenditures are expected to range from $1.1 billion to $1.2 billion.
Investor Verification Checklist
- Biosimilar Impact: Verify the actual market share erosion of EYLEA due to biosimilar launches in the U.S. and Europe versus the transition rate to EYLEA HD.
- Manufacturing Recovery: Confirm the timeline for the Limerick facility to return to full capacity and the resulting impact on Q2 and Q3 gross margins.
- Sanofi Collaboration: Monitor the status of the litigation against Sanofi and its potential impact on the Dupixent profit-sharing arrangement.
- Government Pricing Agreements: Assess the long-term revenue implications of the "Most-Favored-Nation Pricing" agreement with the U.S. government.
- IPR&D Spend: Review the specific details of the $101.9 million in acquired IPR&D expenses to understand the strategic value of recent licensing deals.